X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (422) 422
Publication (66) 66
Book Review (7) 7
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (335) 335
index medicus (280) 280
azacitidine - analogs & derivatives (214) 214
oncology (207) 207
azacitidine - pharmacology (149) 149
dna methylation (149) 149
azacitidine (147) 147
cancer (147) 147
male (143) 143
decitabine (134) 134
azacitidine - therapeutic use (127) 127
female (118) 118
hematology (117) 117
azacitidine - administration & dosage (109) 109
myelodysplastic syndromes (104) 104
aged (103) 103
animals (103) 103
myelodysplastic syndromes - drug therapy (101) 101
acute myeloid-leukemia (97) 97
middle aged (97) 97
methylation (94) 94
azacitidine - pharmacokinetics (93) 93
azacitidine - adverse effects (82) 82
leukemia (81) 81
5-aza-2'-deoxycytidine (80) 80
pharmacology & pharmacy (79) 79
myelodysplastic syndrome (75) 75
antimetabolites, antineoplastic - therapeutic use (74) 74
dna methylation - drug effects (73) 73
treatment outcome (69) 69
cell line, tumor (68) 68
leukemia, myeloid, acute - drug therapy (68) 68
5-azacytidine (66) 66
adult (65) 65
epigenetics (60) 60
research (59) 59
acute myeloid leukemia (56) 56
antimetabolites, antineoplastic - pharmacology (55) 55
care and treatment (54) 54
chemotherapy (54) 54
aged, 80 and over (52) 52
therapy (51) 51
medicine & public health (50) 50
dna (49) 49
dose-response relationship, drug (49) 49
mice (48) 48
article (47) 47
pharmacokinetics (45) 45
gene expression (43) 43
apoptosis (42) 42
deoxyribonucleic acid--dna (42) 42
drug therapy (42) 42
antimetabolites, antineoplastic - adverse effects (40) 40
conventional care regimens (39) 39
antimetabolites, antineoplastic - administration & dosage (38) 38
hematology, oncology and palliative medicine (38) 38
antineoplastic agents - therapeutic use (37) 37
dna modification methylases - antagonists & inhibitors (37) 37
drug administration schedule (37) 37
expression (37) 37
genetic aspects (37) 37
phase-i (37) 37
cells (36) 36
analysis (35) 35
antimetabolites, antineoplastic - pharmacokinetics (35) 35
antineoplastic agents (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
dna methyltransferase (34) 34
health aspects (34) 34
clinical trials as topic (33) 33
enzyme inhibitors - pharmacology (32) 32
antimitotic agents (31) 31
time factors (31) 31
tumors (31) 31
transplantation (30) 30
acute myelogenous leukemia (29) 29
gene expression regulation, neoplastic - drug effects (29) 29
older patients (29) 29
hypomethylating agents (28) 28
leukemia, myeloid, acute - pathology (28) 28
pharmacology/toxicology (28) 28
valproic acid (28) 28
clinical trials (27) 27
patients (27) 27
stem cells (27) 27
cell proliferation - drug effects (26) 26
mds (26) 26
medical research (26) 26
research article (26) 26
apoptosis - drug effects (25) 25
epigenesis, genetic - drug effects (25) 25
leukemia, myeloid, acute - genetics (25) 25
prognosis (25) 25
5-aza-2'-deoxycytidine decitabine (24) 24
cancer therapies (24) 24
demethylation (24) 24
epigenesis, genetic (24) 24
epigenetic therapy (24) 24
medicine (24) 24
cell survival - drug effects (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1240 - 1247
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 12/2017, Volume 268, pp. 92 - 101
Myelodysplastic syndromes (MDS) are a diverse group of bone marrow disorders and clonal hematopoietic stem cell disorders characterized by abnormal blood... 
Bone marrow | Decitabine | Arsenic trioxide | Delivery | Nanoparticle | Myelodysplastic syndrome | APOPTOSIS | DNA METHYLATION | DRUG-DELIVERY | 5-AZACYTIDINE | COMBINATION | CANCER | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | RETINOIC ACID | PHARMACOLOGY & PHARMACY | POLYMER HYBRID NANOPARTICLES | ACUTE PROMYELOCYTIC LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Oxides - chemistry | Azacitidine - chemistry | Phosphatidylethanolamines - therapeutic use | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Alendronate - chemistry | Alendronate - therapeutic use | Tissue Distribution | Arsenicals - therapeutic use | Nanoparticles - therapeutic use | Bone and Bones - metabolism | Phosphatidylethanolamines - pharmacokinetics | Bone Marrow Cells - drug effects | Antineoplastic Agents - pharmacokinetics | Arsenicals - pharmacokinetics | Alendronate - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Oxides - administration & dosage | Azacitidine - administration & dosage | Oxides - therapeutic use | Cell Survival - drug effects | Arsenic Trioxide | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Cells, Cultured | Polyethylene Glycols - pharmacokinetics | Azacitidine - analogs & derivatives | Mice, Transgenic | Phosphatidylethanolamines - administration & dosage | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Oxides - pharmacokinetics | Arsenicals - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Arsenicals - chemistry | Nanoparticles - administration & dosage | Phosphatidylethanolamines - chemistry | Alendronate - administration & dosage | Azacitidine - therapeutic use | Medical research | Medical colleges | Medical examination | Arsenic | Analysis | Medicine, Experimental | Hematopoietic stem cells | Blood | Index Medicus | delivery | nanoparticle | decitabine | arsenic trioxide | bone marrow
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0135520
CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this... 
METHYLATION | RESPONSE CRITERIA | 5-AZACYTIDINE | MULTIDISCIPLINARY SCIENCES | ACUTE MYELOID-LEUKEMIA | DNA METHYLTRANSFERASE INHIBITORS | RISK MYELODYSPLASTIC SYNDROMES | AZACITIDINE | CYTIDINE DEAMINASE | MAMMALIAN-CELLS | INTERNATIONAL WORKING GROUP | Antimetabolites, Antineoplastic - pharmacokinetics | Area Under Curve | Epigenesis, Genetic | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Half-Life | Male | Leukemia, Myelomonocytic, Chronic - drug therapy | Dose-Response Relationship, Drug | DNA Methylation | Antimetabolites, Antineoplastic - blood | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Leukemia, Myelomonocytic, Chronic - pathology | Myelodysplastic Syndromes - drug therapy | Azacitidine - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Leukemia, Myeloid, Acute - pathology | Leukemia, Myelomonocytic, Chronic - mortality | Leukemia, Myeloid, Acute - mortality | Antimetabolites, Antineoplastic - therapeutic use | Myelodysplastic Syndromes - mortality | Survival Analysis | Aged | Myelodysplastic Syndromes - genetics | Myelodysplastic Syndromes - pathology | Azacitidine - blood | Azacitidine - therapeutic use | Leukemia, Myeloid, Acute - genetics | Research | Drug therapy | Pharmacokinetics | Leukemia | Dosing | Myelomonocytic leukemia | Schedules | Medical research | Pharmacodynamics | Myeloid leukemia | Disorders | Cell division | Pharmacology | Exposure | Cancer therapies | Patients | Myelodysplastic syndrome | Chronic myelomonocytic leukemia | Cell cycle | DNA methylation | Epigenetics | Methylation | Drug dosages | Acute myeloid leukemia | Deoxyribonucleic acid--DNA | Deoxyribonucleic acid | DNA
Journal Article
Blood, ISSN 0006-4971, 09/2018, Volume 132, Issue 11, pp. 1125 - 1133
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2008, Volume 61, Issue 5, pp. 759 - 766
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 10, pp. 2285 - 2293
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 25, pp. 6025 - 6031
Journal Article
Asia‐Pacific Journal of Clinical Oncology, ISSN 1743-7555, 06/2018, Volume 14, Issue 3, pp. 270 - 278
Background Azacitidine safety and efficacy were established in studies of mainly Caucasian patients. Differences in drug metabolism enzymes between Caucasian... 
pharmacokinetics | higher risk | myelodysplastic | Chinese | syndromes | azacitidine | Physiological aspects | Myelodysplastic syndromes
Journal Article